Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

PharmaJet presents partner data on immunogenicity with needle-free systems

Closely-held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...

April 27, 2022

Developments

IntelGenx oral film for ED featured in WebMD

The current issue of WebMD features up-and-coming buccal film and buccal patch technologies to deliver drug via the inside lining of the cheek and highlights the sublingual delivery for erectile dysfunction from...

April 21, 2022

Developments

FDA rejects Ampio Pharma proposal for modified filing of Ampion

The FDA rejected Ampio Pharmaceuticals’ (NYSE American:AMPE) proposed modified intent-to-treat (mITT) population as the primary analysis population for evaluating efficacy in the AP-013 trial, and the acceptability of...

April 21, 2022

Developments

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Closely-held LENZ Therapeutics entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment...

April 13, 2022

Developments

Numinus to acquire Novamind creating leader in psychedelic therapy, research

Numinus (TSX:NUMI; OTCQX:NUMIF) agreed to acquire Novamind (CSE:NM; OTCQB:NVMDF;FSE:HN2) in a stock swap, by way of a court-approved plan of arrangement, for total consideration of about $26.2-million (Canadian). The...

April 13, 2022

Developments

Altamira Therapeutics provides business update

Altamira Therapeutics (NASDAQ:CYTO) provided a business update as it repositions around RNA therapeutics and continues to progress towards upcoming key catalysts with its non-RNA legacy programs. “We are...

April 12, 2022

Developments

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

The International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming Altamira Therapeutics’ (NASDAQ:CYTO) positive research findings regarding the in vitro efficacy and safety of its drug...

April 11, 2022

Developments

Viz.ai raises $100-million in Series D round

Closely-held Viz.ai raised $100-million to expand its artificial-intelligence platform designed to detect and triage strokes, heart attacks and aneurysms by scanning patient imagery. The Series D funding round led by...

April 6, 2022

Developments

Cannabotech partners with go NXT LVL to make oncology products in California

Closely-held Cannabotech of Israel entered a new strategic partnership with go NXT LVL of California to develop and manufacturing Cannabotech’s oncology products at go NXT LVL’s facilities in accordance with the...

April 6, 2022

Developments

Australian committee approves Claritas Phase 1 trial of R-107

The Australian Human Research Ethics Committee has approved Claritas Pharmaceuticals’ (TSXV:CLAS; OTC:CLAZF) submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney...

April 5, 2022

Developments

Know Labs receives new foundational U.S. patents

The U.S. Patent and Trademark Office issued two new foundational patents to Know Labs (OTCQB:KNWN) that add significant value to its IP portfolio and proprietary Bio-RFID technology. The first application of the Bio...

April 5, 2022

Developments

Clinigence, Nutex Health complete merger; listing on NASDAQ

Clinigence Holdings (OTC:CLNH) and Nutex Health Holdco completed their business combination. The newly combined company, which will continue under the new name, Nutex Health, brings together two complementary...

April 1, 2022

Developments

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Palisade Bio (NASDAQ:PALI) received a “study may proceed” letter from the FDA for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing...

March 22, 2022

Developments

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Closely-held Cytovale announced that a new study of its investigational IntelliSep test has been published in the peer-reviewed journal, PLOS ONE. The study demonstrated that the IntelliSep test has the potential to...

March 17, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Developments

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Altamira Therapeutics (NASDAQ:CYTO) completed patient enrollment with its Bentrio nasal spray in a house dust mite allergic rhinitis trial and expects to release top-line results from the trial during the second quarter...

March 15, 2022

Developments

Profound Medical CEO adds to holdings

Profound Medical (NASDAQ:PROF; TSX:PRN) chairman and CEO, Arun Menawat, acquired a total of 60,599 shares of Profound on the open market at a cost of $497,180 (U.S.). According to a filing with SEDI, Dr. Menawat...

March 11, 2022

Developments

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira Therapeutics (NASDAQ:CYTO) reported positive efficacy data from testing its Bentrio nasal spray in vitro against the Omicron variant of the SARS-CoV-2 virus. Bentrio is a drug-free nasal spray for protection...

March 11, 2022

Developments

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Altamira Therapeutics’ (NASDAQ:CYTO) affiliate, Altamira Medica, has received the necessary approvals to initiate a clinical investigation of its Bentrio nasal spray in COVID-19 patients. The COVAMID study is a...

March 9, 2022

Developments

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Closely-held Cannabotech of Israel reports that its cell model study results have shown that its integrative colon products killed more than 90% of colon cancer cells in a cell model experiment. The integrative colon...

March 7, 2022

Developments

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Altamira Therapeutics (NASDAQ:CYTO) entered into an exclusive licensing and distribution agreement with Nuance Pharma for Altamira’s Bentrio nasal spray for protection against airborne viruses and allergens in the...

March 4, 2022

Developments

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

Aravive (NASDAQ:ARAV) reported positive new data from the Phase 1b portion of an ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell cancer (ccRCC) and new data from a biomarker high subgroup. Key findings...

March 3, 2022

PharmaJet presents partner data on immunogenicity with needle-free systems

IntelGenx oral film for ED featured in WebMD

FDA rejects Ampio Pharma proposal for modified filing of Ampion

LENZ Therapeutics and JIXING in exclusive greater China license agreement

Numinus to acquire Novamind creating leader in psychedelic therapy, research

Altamira Therapeutics provides business update

Altamira data in SARS-CoV-2 Delta variant with Bentrio published in IJMS

Viz.ai raises $100-million in Series D round

Cannabotech partners with go NXT LVL to make oncology products in California

Australian committee approves Claritas Phase 1 trial of R-107

Know Labs receives new foundational U.S. patents

Clinigence, Nutex Health complete merger; listing on NASDAQ

Palisade Bio receives FDA okay for Phase 3 trial for return of bowel function

Cytovale IntelliSep study data to risk-stratify patients published in PLOS ONE

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Altamira completes patient enrollment in house dust mite allergy trial with Bentrio

Profound Medical CEO adds to holdings

Altamira posts positive in vitro efficacy data for Bentrio against Omicron variant

Altamira cleared for clinical trial with Bentrio to treat COVID-19

Cannabotech technology eliminated 90%-plus of colon cancer cells in cell model

Altamira, Nuance in pact to distribute Bentrio in China, other Asian markets

Aravive posts positive updated Phase 1b data in clear cell renal cell carcinoma

General

More